Company: CGCT
Filing Date: 2025-04-03
Form Type: S-1/A
Source: 0001104659-25-031359
Chunk: 3

Company: Cartesian Growth Corp III
Filing Date: 2025-04-03
Form: S-1/A
Chunk 3
---
 directors against the cost of defense, settlement or payment of a judgment
in some circumstances and insures us against our obligations to indemnify our officers and directors.

Our officers and directors have agreed to waive
any right, title, interest or claim of any kind in or to any monies in the trust account, and have agreed to waive any right, title,
interest or claim of any kind they may have in the future as a result of, or arising out of, any services provided to us and will not
seek recourse against the trust account for any reason whatsoever (except to the extent they are entitled to funds from the trust account
due to their ownership of public shares). Accordingly, any indemnification provided will only be able to be satisfied by us if (i) we
have sufficient funds outside of the trust account or (ii) we consummate an initial business combination.

Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have
been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is
therefore unenforceable.

Item 15. Recent Sales of Unregistered Securities.

Pursuant to certain subscription agreements dated
October 29, 2024, on November 12, 2024, CGC III Sponsor LLC, our sponsor, and CGC III Sponsor DirectorCo LLC, or DirectorCo,
paid an aggregate of $25,000, or approximately $0.004 per share, to cover certain of our offering costs in exchange for an aggregate
of 5,750,000 Class B ordinary shares. Such securities were issued in connection with our organization pursuant to the exemption
from registration contained in Section 4(a)(2) of the Securities Act. The number of founder shares outstanding was determined
based on the expectation that the total size of this offering would be a maximum of 23,000,000 units if the underwriters’
over-allotment option is exercised in full and therefore that such founder shares would represent 20% of the outstanding ordinary shares
after this offering. Up to 750,000 of these shares will be surrendered by our sponsor to us for no consideration depending on the extent
to which the underwriters’ over-allotment option is exercised.

Each of our sponsor and DirectorCo is an accredited
investor for purposes of Rule 501 of Regulation D. Each of the equity holders in our